Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

General

Immix Biopharma Reports 75% Complete Response Rate And 31.5-Month Ongoing Best Response Duration For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis At ASH 2024, Highlighting Phase 1/2 Data With Median Four Prior Therapy Lines - Immix Biopharma (NASDAQ:IMMX)

Benzinga Newsdesk

Immix Biopharma

IMMX

Immix Biopharma Reports 75% Complete Response Rate And 31.5-Month Ongoing Best Response Duration For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis At ASH 2024, Highlighting Phase 1/2 Data With Median Four Prior Therapy Lines

Comments